Get the latest news, insights, and market updates on FBRX (Forte Biosciences, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Forte Biosciences, Inc. Announces Results and Provides Update
DALLAS, August 14, 2025--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its second quarter 2025 financial results and provided a business update. Aug 14, 2025 - $FBRX
Top Midday Decliners
Torrid's (CURV) shares sank 38% amid heavy trading after the company said late Tuesday that it price Jun 25, 2025 - $FBRX
Forte Biosciences Announces Pricing of $75 Million Public Offering
DALLAS, June 25, 2025--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,630,450 shares of its common stock at a price to the public of $12.00 per share and, in lieu of common stock to certain investors who so chose, pre-funded warrants to purchase up to 619,606 shares of common stock at a price to the public of $11.999 per pre-funded warrant, which repres Jun 25, 2025 - $FBRX
Forte Biosciences Announces Proposed Public Offering
DALLAS, June 24, 2025--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of Jun 24, 2025 - $FBRX
Forte Biosciences announces data from trial in celiac disease for FB102
Forte Biosciences (FBRX) announced data from a Phase 1b trial in celiac disease for lead program FB102. The FB102-101 Phase 1b celiac disease study enrolled 32 subjects 3:1 randomized. Subjects received 4 doses of FB102 and underwent a 16-day gluten challenge. In addition to safety and tolerability, the study assessed morphologic and inflammatory endpoints along with gluten challenge induced symptoms. FB102 demonstrated a statistically significant benefit on the composite histological VCIEL endp Jun 24, 2025 - $FBRX
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
DALLAS, June 23, 2025--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). Jun 23, 2025 - $FBRX
Forte Biosciences, Inc. Announces Results and Provides Clinical Update
DALLAS, March 31, 2025--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced full year 2024 results and provides a clinical update. Mar 31, 2025 - $FBRX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple